Never Mind: Ozempic Patents Not Fully In The Clear At PTAB
The Patent Trial and Appeal Board on Wednesday granted Mylan's request to review whether a patent covering Novo Nordisk's blockbuster drug Ozempic holds up, just two days after clearing the Danish...To view the full article, register now.
Already a subscriber? Click here to view full article